Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 14/20 | 0.54 |
| ▸ | SRPK1 | Q96SB4 | 5/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | SRPK2 | P78362 | 4/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30468512 | 0.98 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| Hydrochloric Acid SCHEMBL29051922 | 0.98 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| Acetic Acid SCHEMBL1627284 | 0.93 | PTK2 (0.49) | PTK2SRPK1PTK2B | |
| SCHEMBL10229210 | 0.87 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| Methane SCHEMBL4887418 | 0.86 | PTK2 (0.44) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| SCHEMBL16569929 | 0.85 | PTK2 (0.52) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| SCHEMBL16570123 | 0.84 | PTK2 (0.51) | PTK2SRPK1PTK2BSRPK2SRPK3 | |
| SCHEMBL17993894 | 0.83 | PTK2 (0.40) | PTK2SRPK1SRPK2 | |
| SCHEMBL1291246 | 0.81 | ALDH1A1 (0.39) | PTK2SRPK1 | |
| SCHEMBL12586298 | 0.81 | PTK2 (0.58) | PTK2SRPK1PTK2BSRPK2SRPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852119-A | Light affinity probe for targeting local focal adhesion kinase and preparation method and application thereof | 南京科络思生物科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118852119-A | Light affinity probe for targeting local focal adhesion kinase and preparation method and application thereof | 南京科络思生物科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118852119-A | Light affinity probe for targeting local focal adhesion kinase and preparation method and application thereof | 南京科络思生物科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11981665-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | CHEN ZHIHONG (US) | 2024-05-14 | — | — | US | disclosed |
| CN-111683662-B | Substituted pyrimidine compounds, pharmaceutical compositions and methods of treatment | 陈志宏 | 2024-04-02 | — | — | CN | disclosed |
| US-20230109688-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CHEN ZHIHONG (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3675860-B1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | ZHIHONG CHEN (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11440904-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | CHEN ZHIHONG (US) | 2022-09-13 | — | — | US | disclosed |
| CN-111683662-A | Substituted pyrimidines, pharmaceutical compositions and methods of treatment | 陈志宏 | 2020-09-18 | — | — | CN | disclosed |
| EP-3675860-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Zhihong, Chen (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2009071535-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| CN-101346380-A | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER PROD INC (US) | 2009-01-14 | — | — | CN | disclosed |
| WO-2008129380-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1966207-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072158-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | PTK2 2406/4885SRPK1 218/4885PTK2B 1390/4885 |
| US-20230109688-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | BTK, PTK2, LCK | PTK2 2/4885SRPK1 643/4885PTK2B 7/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885SRPK1 518/4885PTK2B 3523/4885 |
| US-11981665-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | BTK, PTK2, LCK | PTK2 2/4885SRPK1 643/4885PTK2B 7/4885 |
| US-11440904-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | BTK, PTK2, LCK | PTK2 2/4885SRPK1 643/4885PTK2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.